Editorial: Systemic sclerosis: immunological impacts

At the molecular level, Wu et al. identify NOX4 and NEK6 as shared elements linking SSc and sarcopenia through integrative transcriptomics and machine learning (2). Their findings highlight convergence within oxidative-immune regulatory networks beneath divergent clinical phenotypes, suggesting that heterogeneous manifestations may arise from intersecting molecular control points rather than isolated pathogenic cascades. Rather than targeting a single cytokine, this strategy recalibrates a central regulatory brake within the immune-fibrotic network, illustrating how pathway-level modulation can exert broad downstream influence.Clinical translation of layered intervention is exemplified by Fu et al., who report stabilization of severe cardiac involvement using sequential cyclophosphamide followed by tocilizumab (5). This phased modulation of immune axes demonstrates that multi-level therapeutic strategies can reverse life-threatening organ manifestations, supporting the concept of systemic recalibration through coordinated intervention.Finally, recent comprehensive analyses of SSc pathogenesis emphasize the intricate interplay among immune activation, cytokine networks, TGF-β-driven fibroblast signaling, and extracellular matrix remodeling (6). This multidimensional framework underscores the density and redundancy of immune-fibrotic interactions in SSc. In such a networked context, therapeutic impact may depend less on suppressing isolated mediators and more on understanding where coordinated regulatory influence can propagate across layers.Collectively, these studies define a vertically organized regulatory architecture encompassing serological structure, molecular convergence, fibrinolytic-vascular balance, regulatory brake restoration, clinical layered intervention, and upstream immune modulation.Although SSc appears clinically heterogeneous, structural analysis reveals points where multiple regulatory processes intersect. These are not necessarily the most abundant mediators but loci where distinct layers converge.Rather than expanding catalogs of dysregulated molecules, future progress may depend on clarifying how regulatory layers interact and where convergence occurs. A structurally informed perspective may therefore support more precise and reproducible therapeutic strategies in complex autoimmune disease.